Published in J Bacteriol on July 30, 2010
Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis (2012) 4.34
Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin Infect Dis (2013) 3.15
Clinical Clostridium difficile: clonality and pathogenicity locus diversity. PLoS One (2011) 2.04
Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol (2013) 1.52
Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes. J Clin Microbiol (2011) 1.37
Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol (2011) 1.34
Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response. Gut Microbes (2012) 1.33
Spores of Clostridium difficile clinical isolates display a diverse germination response to bile salts. PLoS One (2012) 1.31
Characterisation and carriage ratio of Clostridium difficile strains isolated from a community-dwelling elderly population in the United Kingdom. PLoS One (2011) 1.29
From stool transplants to next-generation microbiota therapeutics. Gastroenterology (2014) 1.29
The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog (2011) 1.28
Reconsidering the sporulation characteristics of hypervirulent Clostridium difficile BI/NAP1/027. PLoS One (2011) 1.24
Clostridium difficile infection: new insights into management. Mayo Clin Proc (2012) 1.23
Toward a structural understanding of Clostridium difficile toxins A and B. Front Cell Infect Microbiol (2012) 1.22
Recombinational switching of the Clostridium difficile S-layer and a novel glycosylation gene cluster revealed by large-scale whole-genome sequencing. J Infect Dis (2012) 1.21
Clostridium difficile isolates with increased sporulation: emergence of PCR ribotype 002 in Hong Kong. Eur J Clin Microbiol Infect Dis (2011) 1.18
Adaptive strategies and pathogenesis of Clostridium difficile from in vivo transcriptomics. Infect Immun (2013) 1.17
The relationship between phenotype, ribotype, and clinical disease in human Clostridium difficile isolates. Anaerobe (2013) 1.14
Clostridium difficile infection in the twenty-first century. Emerg Microbes Infect (2013) 1.09
Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB. PLoS Pathog (2013) 1.08
Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect Dis (2010) 1.04
Laboratory diagnosis of bacterial gastroenteritis. Clin Microbiol Rev (2015) 1.03
TcdC does not significantly repress toxin expression in Clostridium difficile 630ΔErm. PLoS One (2012) 1.02
The second messenger cyclic Di-GMP regulates Clostridium difficile toxin production by controlling expression of sigD. J Bacteriol (2013) 1.00
Surface-layer protein A (SlpA) is a major contributor to host-cell adherence of Clostridium difficile. PLoS One (2013) 1.00
Clostridium difficile infection. Nat Rev Dis Prim (2016) 0.99
Variations in virulence and molecular biology among emerging strains of Clostridium difficile. Microbiol Mol Biol Rev (2013) 0.99
Functional characterization of Clostridium difficile spore coat proteins. J Bacteriol (2013) 0.98
Spore formation and toxin production in Clostridium difficile biofilms. PLoS One (2014) 0.98
Fourteen-genome comparison identifies DNA markers for severe-disease-associated strains of Clostridium difficile. J Clin Microbiol (2011) 0.98
Role of fecal Clostridium difficile load in discrepancies between toxin tests and PCR: is quantitation the next step in C. difficile testing? Eur J Clin Microbiol Infect Dis (2012) 0.96
The membrane as a target for controlling hypervirulent Clostridium difficile infections. J Antimicrob Chemother (2012) 0.96
Rapid diagnosis of Clostridium difficile infection by multiplex real-time PCR. Eur J Clin Microbiol Infect Dis (2011) 0.96
Mechanisms of hypervirulent Clostridium difficile ribotype 027 displacement of endemic strains: an epidemiological model. Sci Rep (2015) 0.96
Sequence similarity of Clostridium difficile strains by analysis of conserved genes and genome content is reflected by their ribotype affiliation. PLoS One (2014) 0.95
Protective efficacy induced by recombinant Clostridium difficile toxin fragments. Infect Immun (2013) 0.94
TcdB from hypervirulent Clostridium difficile exhibits increased efficiency of autoprocessing. Mol Microbiol (2012) 0.93
Interactions Between the Gastrointestinal Microbiome and Clostridium difficile. Annu Rev Microbiol (2015) 0.93
Modeling the role of peroxisome proliferator-activated receptor γ and microRNA-146 in mucosal immune responses to Clostridium difficile. PLoS One (2012) 0.93
Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortality. Eur J Clin Microbiol Infect Dis (2014) 0.92
CodY-Dependent Regulation of Sporulation in Clostridium difficile. J Bacteriol (2016) 0.92
Prospects for flavonoid and related phytochemicals as nature-inspired treatments for Clostridium difficile infection. J Appl Microbiol (2014) 0.90
Effects of ciprofloxacin on the expression and production of exotoxins by Clostridium difficile. J Med Microbiol (2013) 0.90
Variation in germination of Clostridium difficile clinical isolates correlates to disease severity. Anaerobe (2015) 0.88
CdtR Regulates TcdA and TcdB Production in Clostridium difficile. PLoS Pathog (2016) 0.87
Clostridium difficile--a moving target. F1000 Med Rep (2011) 0.85
Comparative transcriptional analysis of clinically relevant heat stress response in Clostridium difficile strain 630. PLoS One (2012) 0.85
Phenotypic and genotypic analysis of Clostridium difficile isolates: a single-center study. J Clin Microbiol (2014) 0.85
Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile. J Antimicrob Chemother (2014) 0.84
The potential for emerging therapeutic options for Clostridium difficile infection. Gut Microbes (2014) 0.84
Decreasing Clostridium difficile infections by an antimicrobial stewardship program that reduces moxifloxacin use. Antimicrob Agents Chemother (2014) 0.84
Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med (2016) 0.83
Epidemic Clostridium difficile strains demonstrate increased competitive fitness compared to nonepidemic isolates. Infect Immun (2014) 0.83
Hype or hypervirulence: a reflection on problematic C. difficile strains. Virulence (2013) 0.83
Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile. Antimicrob Agents Chemother (2015) 0.83
Humanized microbiota mice as a model of recurrent Clostridium difficile disease. Microbiome (2015) 0.82
Clostridium difficile TcdC protein binds four-stranded G-quadruplex structures. Nucleic Acids Res (2013) 0.82
Conformational analysis of Clostridium difficile toxin B and its implications for substrate recognition. PLoS One (2012) 0.81
Discovery and development of surotomycin for the treatment of Clostridium difficile. J Ind Microbiol Biotechnol (2015) 0.80
Susceptibility of hamsters to Clostridium difficile isolates of differing toxinotype. PLoS One (2013) 0.80
Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review. Curr Top Med Chem (2014) 0.79
Using phenotype microarrays to determine culture conditions that induce or repress toxin production by Clostridium difficile and other microorganisms. PLoS One (2013) 0.79
Carvacrol and trans-cinnamaldehyde reduce Clostridium difficile toxin production and cytotoxicity in vitro. Int J Mol Sci (2014) 0.78
Proteomic Analysis and Label-Free Quantification of the Large Clostridium difficile Toxins. Int J Proteomics (2013) 0.78
The Regulatory Networks That Control Clostridium difficile Toxin Synthesis. Toxins (Basel) (2016) 0.78
Evolutionary clade affects resistance of Clostridium difficile spores to Cold Atmospheric Plasma. Sci Rep (2017) 0.78
Effect of airborne hydrogen peroxide on spores of Clostridium difficile. Wien Klin Wochenschr (2014) 0.77
Diarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cells. Bioorg Med Chem Lett (2013) 0.77
Predominance and high antibiotic resistance of the emerging Clostridium difficile genotypes NAPCR1 and NAP9 in a Costa Rican hospital over a 2-year period without outbreaks. Emerg Microbes Infect (2016) 0.76
Clostridium difficile in the Long-Term Care Facility: Prevention and Management. Curr Geriatr Rep (2015) 0.76
Deciphering Adaptation Strategies of the Epidemic Clostridium difficile 027 Strain during Infection through In Vivo Transcriptional Analysis. PLoS One (2016) 0.76
Newly identified bacteriolytic enzymes that target a wide range of clinical isolates of Clostridium difficile. Biotechnol Bioeng (2016) 0.76
Characterization of Clostridium difficile Strains in British Columbia, Canada: A Shift from NAP1 Majority (2008) to Novel Strain Types (2013) in One Region. Can J Infect Dis Med Microbiol (2016) 0.76
A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile. BMC Infect Dis (2016) 0.75
Determining Clostridium difficile intra-taxa diversity by mining multilocus sequence typing databases. BMC Microbiol (2017) 0.75
A genetic switch controls the production of flagella and toxins in Clostridium difficile. PLoS Genet (2017) 0.75
Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes. Can J Infect Dis Med Microbiol (2016) 0.75
A novel subtyping assay for detection of Clostridium difficile virulence genes. J Mol Diagn (2014) 0.75
Clinical Characteristics and Treatment Outcomes of Clostridium difficile Infections by PCR Ribotype 017 and 018 Strains. PLoS One (2016) 0.75
Analysis of TcdB Proteins within the Hypervirulent Clade 2 Reveals an Impact of RhoA Glucosylation on Clostridium difficile Proinflammatory Activities. Infect Immun (2016) 0.75
Treatment of Clostridium difficile infection: recent trial results. Clin Investig (Lond) (2013) 0.75
Bile acid sensitivity and in vivo virulence of clinical Clostridium difficile isolates. Anaerobe (2016) 0.75
Reprofiled anthelmintics abate hypervirulent stationary-phase Clostridium difficile. Sci Rep (2016) 0.75
An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection. PLoS One (2017) 0.75
Pathogenicity Locus, Core Genome, and Accessory Gene Contributions to Clostridium difficile Virulence. MBio (2017) 0.75
Cwp2 from Clostridium difficile exhibits an extended three domain fold and cell adhesion in vitro. FEBS J (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res (1994) 392.47
The RAST Server: rapid annotations using subsystems technology. BMC Genomics (2008) 175.18
An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med (2005) 18.10
A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med (2005) 16.59
Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet (2005) 12.54
The Vienna RNA websuite. Nucleic Acids Res (2008) 9.02
Toxin B is essential for virulence of Clostridium difficile. Nature (2009) 5.49
A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol (1998) 4.79
Rapid, accurate, computational discovery of Rho-independent transcription terminators illuminates their relationship to DNA uptake. Genome Biol (2007) 4.27
Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology (2009) 3.29
Comparative phylogenomics of Clostridium difficile reveals clade specificity and microevolution of hypervirulent strains. J Bacteriol (2006) 3.05
Definition of the single integration site of the pathogenicity locus in Clostridium difficile. Gene (1996) 2.87
A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec. Clin Infect Dis (2006) 2.85
Hospitals battling outbreaks of C. difficile. CMAJ (2004) 2.76
Construction and analysis of chromosomal Clostridium difficile mutants. Mol Microbiol (2006) 2.65
Multilocus variable-number tandem-repeat analysis for investigation of Clostridium difficile transmission in Hospitals. J Clin Microbiol (2006) 2.52
tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol (2006) 2.49
Repression of Clostridium difficile toxin gene expression by CodY. Mol Microbiol (2007) 2.28
Regulated transcription of Clostridium difficile toxin genes. Mol Microbiol (1998) 2.28
Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile. Eur J Biochem (1997) 2.25
Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol (2007) 2.05
Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1. J Clin Microbiol (2008) 1.98
Clinical features of Clostridium difficile-associated infections and molecular characterization of strains: results of a retrospective study, 2000-2004. Infect Control Hosp Epidemiol (2007) 1.90
Clinical severity of Clostridium difficile PCR ribotype 027: a case-case study. PLoS One (2008) 1.88
Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J Clin Microbiol (2006) 1.71
Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis (2002) 1.68
Suppression of toxin production in Clostridium difficile VPI 10463 by amino acids. Microbiology (1999) 1.61
Characterization of the sporulation initiation pathway of Clostridium difficile and its role in toxin production. J Bacteriol (2009) 1.57
Update of Clostridium difficile-associated disease due to PCR ribotype 027 in Europe. Euro Surveill (2007) 1.55
Comparative analysis of BI/NAP1/027 hypervirulent strains reveals novel toxin B-encoding gene (tcdB) sequences. J Med Microbiol (2008) 1.54
Infection of hamsters with epidemiologically important strains of Clostridium difficile. J Infect Dis (2001) 1.52
Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother (2007) 1.35
Prevalence of Clostridium difficile environmental contamination and strain variability in multiple health care facilities. Am J Infect Control (2007) 1.35
Multicenter typing comparison of sporadic and outbreak Clostridium difficile isolates from geographically diverse hospitals. J Infect Dis (1997) 1.32
First isolation of Clostridium difficile 027 in Japan. Euro Surveill (2007) 1.23
Induction of toxins in Clostridium difficile is associated with dramatic changes of its metabolism. Microbiology (2008) 1.20
Emergence of Clostridium difficile toxinotype III, PCR-ribotype 027-associated disease, France, 2006. Euro Surveill (2006) 1.03
UV-visible marker confirms that environmental persistence of Clostridium difficile spores in toilets of patients with C. difficile-associated diarrhea is associated with lack of compliance with cleaning protocol.e. BMC Infect Dis (2008) 0.90
An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med (2005) 18.10
Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol (2010) 17.99
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis (2006) 14.63
Burden of Clostridium difficile infection in the United States. N Engl J Med (2015) 8.17
Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol (2009) 7.89
Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med (2010) 7.37
Toxin B is essential for virulence of Clostridium difficile. Nature (2009) 5.49
Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol (2009) 3.66
A mouse model of Clostridium difficile-associated disease. Gastroenterology (2008) 3.65
Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis (2008) 3.32
Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis (2010) 3.31
Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology (2009) 3.29
Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis (2007) 3.15
Strategies to prevent central line-associated bloodstream infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 3.13
Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect (2007) 2.84
Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med (2013) 2.78
An outbreak of eosinophilic meningitis caused by Angiostrongylus cantonensis in travelers returning from the Caribbean. N Engl J Med (2002) 2.76
Multilocus variable-number tandem-repeat analysis for investigation of Clostridium difficile transmission in Hospitals. J Clin Microbiol (2006) 2.52
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother (2007) 2.43
Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. Gut (2003) 2.37
A compendium of strategies to prevent healthcare-associated infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 2.32
Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol (2010) 2.32
Strategies to prevent catheter-associated urinary tract infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 2.30
Strategies to prevent surgical site infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 2.22
Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J Infect Dis (2006) 1.99
Toxinotype V Clostridium difficile in humans and food animals. Emerg Infect Dis (2008) 1.98
Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis (2004) 1.98
A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis (2004) 1.96
Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis (2012) 1.96
Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine (2009) 1.85
Strategies to prevent clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 1.84
Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother (2008) 1.84
Strategies to prevent ventilator-associated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol (2008) 1.81
Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis (2002) 1.68
Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals. Infect Control Hosp Epidemiol (2008) 1.66
Comparison of strain typing results for Clostridium difficile isolates from North America. J Clin Microbiol (2011) 1.65
Staphylococcus aureus and Clostridium difficile cause distinct pseudomembranous intestinal diseases. Clin Infect Dis (2004) 1.58
Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol (2004) 1.52
Effectiveness of alcohol-based hand rubs for removal of Clostridium difficile spores from hands. Infect Control Hosp Epidemiol (2010) 1.51
Identification and temperature regulation of Legionella pneumophila genes involved in type IV pilus biogenesis and type II protein secretion. Infect Immun (1998) 1.51
Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. difficile infections: 2005-2007. Anaerobe (2009) 1.47
Workshop on research priorities for management and treatment of angiostrongyliasis(1). Emerg Infect Dis (2012) 1.43
Morphogenesis of the Bacillus anthracis spore. J Bacteriol (2006) 1.43
Frequency of binary toxin genes among Clostridium difficile strains that do not produce large clostridial toxins. J Clin Microbiol (2003) 1.43
Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis (2012) 1.42
Predictors of death after Clostridium difficile infection: a report on 128 strain-typed cases from a teaching hospital in the United Kingdom. Clin Infect Dis (2010) 1.41
Enteropathogenic Escherichia coli EspG disrupts microtubules and in conjunction with Orf3 enhances perturbation of the tight junction barrier. Mol Microbiol (2005) 1.40
Molecular epidemiology of Clostridium difficile over the course of 10 years in a tertiary care hospital. Clin Infect Dis (2009) 1.39
Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response. Gut Microbes (2012) 1.33
Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother (2011) 1.33
Balance of bacterial pro- and anti-inflammatory mediators dictates net effect of enteropathogenic Escherichia coli on intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol (2005) 1.32
NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis (2014) 1.31
Infection of hamsters with historical and epidemic BI types of Clostridium difficile. J Infect Dis (2007) 1.29
Revised nomenclature of Clostridium difficile toxins and associated genes. J Med Microbiol (2005) 1.28
Taxonomy and phylogeny of the Fusarium dimerum species group. Mycologia (2009) 1.24
International typing study of toxin A-negative, toxin B-positive Clostridium difficile variants. J Clin Microbiol (2003) 1.23
Metronidazole for Clostridium difficile-associated disease: is it okay for Mom? Clin Infect Dis (2005) 1.21
Tuberculous tenosynovitis. Hum Pathol (2004) 1.21
Multilocus variable-number tandem-repeat analysis and multilocus sequence typing reveal genetic relationships among Clostridium difficile isolates genotyped by restriction endonuclease analysis. J Clin Microbiol (2009) 1.21
Clostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventions. Gut Microbes (2010) 1.19
Enteropathogenic E. coli non-LEE encoded effectors NleH1 and NleH2 attenuate NF-κB activation. Mol Microbiol (2010) 1.18
lbtA and lbtB are required for production of the Legionella pneumophila siderophore legiobactin. J Bacteriol (2006) 1.17
Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr (2004) 1.16
Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe (2009) 1.15
Difference in the incidence of Clostridium difficile among patients infected with human immunodeficiency virus admitted to a public hospital and a private hospital. Infect Control Hosp Epidemiol (2002) 1.15
Predominance of a single restriction endonuclease analysis group with intrahospital subgroup diversity among Clostridium difficile isolates at two Chicago hospitals. Infect Control Hosp Epidemiol (2002) 1.14
Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters. J Infect Dis (2003) 1.14
Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother (2012) 1.13
Identification of novel pathogenicity loci in Clostridium perfringens strains that cause avian necrotic enteritis. PLoS One (2010) 1.13
Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin Infect Dis (2011) 1.07